{"filings":[{"id":77484,"accession_number":"0001193125-26-222750","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2026-05-14T11:05:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint receives third positive DSMC recommendation for Phase 3 wet AMD DURAVYU trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMC recommends LUGANO and LUCIA continue without modification; all active treatment-arm patients have received second DURAVYU dose.","Over 35% of patients have received third planned dose at Week 56; safety profile consistent with >190 patients across prior trials.","Topline data from LUGANO expected mid-2026; LUCIA readout to follow shortly after.","Trials enroll over 900 patients; primary endpoint is non-inferiority in mean BCVA change at weeks 52 and 56."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92035,"accession_number":"0001193125-26-207537","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint Q1 net loss $84.8M ($0.99/share); DURAVYU Phase 3 wet AMD data expected mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $0.7M vs $24.5M YoY, driven by YUTIQ license deferral; operating expenses $87.9M.","Cash & investments $223M at March 31, 2026, runway into Q4 2027; down from $306M at year-end 2025.","Phase 3 wet AMD trials (LUGANO/LUCIA) topline data due mid-2026; over 900 patients enrolled.","Phase 3 DME trials (COMO/CAPRI) >1/3 enrolled; full enrollment expected Q3 2026, topline Q4 2027.","New ARVO 2026 data show vorolanib inhibits JAK1/IL-6, supporting multi-mechanism anti-inflammatory effect."],"consensus_eps_estimate":-0.8136,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":696000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92034,"accession_number":"0001193125-26-152852","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint posts updated investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation posted on April 13, 2026 on company website.","Presentation content not available in this filing; no specific numbers or events provided.","Ticker: EYPT; previous presentations may be superseded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102522,"accession_number":"0001193125-26-117745","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"EyePoint files defamation lawsuit against Ocular Therapeutix over false statements about DURAVYU","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Complaint filed March 20, 2026 in Middlesex County Superior Court (Massachusetts).","Alleges Ocular Therapeutix made false/misleading representations about EyePoint's lead product DURAVYU (vorolanib intravitreal insert).","Claims include defamation, commercial disparagement, violation of Mass. Gen. L. c. 93A, and tortious interference.","Seeks injunctive relief, public retraction, monetary damages, attorneys' fees, and other relief.","EyePoint asserts defendant's actions harmed its business relations and clinical results reputation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102521,"accession_number":"0001193125-26-089856","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint Q4 net loss $67.6M; DURAVYU wet AMD Phase 3 topline due mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $67.6M ($0.81/sh) vs $41.4M ($0.64); FY net loss $232M ($3.17) vs $130.9M ($2.32).","Total net revenue Q4 $0.6M vs $11.6M, mainly from YUTIQ deferred revenue recognition.","Cash, cash equivalents & investments $306M as of Dec 31, 2025; provides runway into Q4 2027.","Both Phase 3 wet AMD trials (LUGANO, LUCIA) on track; topline data expected mid-2026. DME trials dosed.","Appointed Michael Campbell as Chief Commercial Officer for DURAVYU launch readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102520,"accession_number":"0001193125-26-084154","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint doses first patients in Phase 3 DME trials for DURAVYU; topline data 2H 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patients dosed in global Phase 3 COMO and CAPRI trials of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema.","DURAVYU is a sustained-release TKI inhibiting VEGF, PDGF, and IL-6; design based on positive Phase 2 VERONA results.","Non-inferiority trials vs aflibercept; ~240 patients each; primary endpoint BCVA change at weeks 52 and 56.","DURAVYU 2.7mg administered via standard intravitreal injection every six months; topline data anticipated 2H 2027.","Program aligns with FDA and EMA after End of Phase 2 meeting; aims to reduce treatment burden for DME patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102519,"accession_number":"0001193125-26-005418","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint provides 2026 clinical milestones; ~$300M cash; wet AMD data mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 LUGANO (432 pts) wet AMD top-line data expected mid-2026; LUCIA (475 pts) data to follow.","Phase 3 DME program (COMO/CAPRI) first patient dosing expected Q1 2026; ~240 pts each.","Preliminary cash & investments ~$300M at Dec 31, 2025; runway into Q4 2027.","DSMC second review recommended continuation of Phase 3 program with no protocol changes.","Presenting at J.P. Morgan Healthcare Conference on Jan 13, 2026 at 7:30 a.m. PT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118790,"accession_number":"0001193125-25-310731","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"EyePoint Pharmaceuticals renamed to EyePoint, Inc. effective Dec 8, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corporate name changed to EyePoint, Inc.; no change to ticker symbol EYPT.","Name change effective December 8, 2025; CUSIP remains 30233G209.","Stockholder rights unaffected; common stock continues on Nasdaq under EYPT.","No other amendments to certificate or by-laws beside the name change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118789,"accession_number":"0001193125-25-286961","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint DSMC gives positive recommendation for Phase 3 DURAVYU wet AMD trials; no protocol changes","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DSMC completed second scheduled review of Phase 3 LUGANO and LUCIA trials; no modifications recommended.","All patients reached Week 8; ~25% received second planned DURAVYU dose at Week 32.","Masked safety data shows no safety signals, consistent with prior DURAVYU trials.","Topline 56-week data for LUGANO on track for mid-2026; LUCIA data to follow closely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118788,"accession_number":"0001193125-25-270145","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint Pharmaceuticals files $200M ATM equity offering with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered at-the-market offering of up to $200 million of common stock under a prospectus supplement filed November 6, 2025.","Sales agreement with Cantor Fitzgerald & Co. dated August 5, 2020 governs the offering.","Proceeds expected for general corporate purposes; legal opinion from Hogan Lovells filed as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118787,"accession_number":"0001193125-25-265706","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint Q3 net revenue $1.0M, net loss $59.7M; DURAVYU Phase 3 fully enrolled; $172.5M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 total net revenue fell to $1.0M from $10.5M YoY; net loss widened to $59.7M ($0.85/share) vs $29.4M ($0.54/share).","Cash, equivalents & securities $204M at Sep 30; Oct public offering added $162M net, extending runway into Q4 2027.","Phase 3 LUGANO/LUCIA for wet AMD fully enrolled (>900 patients); topline data expected mid-2026, first-to-market target.","Initiated pivotal Phase 3 DME program (COMO, CAPRI) with FDA non-inferiority pathway; first dosing in Q1 2026.","Preclinical data shows DURAVYU inhibits IL-6 inflammation plus VEGF, supporting multi-target mechanism in retina."],"consensus_eps_estimate":-0.8005,"consensus_eps_actual":-2.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":30751000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118786,"accession_number":"0001193125-25-241639","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"EyePoint raises ~$150M in public offering to fund DURAVYU clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing: 11M shares at $12.00 each; 1.5M pre-funded warrants at $11.999 each.","Gross proceeds ~$150M; net proceeds after underwriting discounts ~$141M.","Net proceeds to advance DURAVYU for wet AMD and DME, plus pipeline and general purposes.","Underwriters have 30-day option for up to 1,875,000 additional shares at $12.00.","Offering closed on October 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118785,"accession_number":"0001193125-25-239008","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"EyePoint initiates Phase 3 DURAVYU DME program; first patient Q1 2026; dual MOA data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosing in pivotal Phase 3 DME trials (COMO and CAPRI) expected Q1 2026; trials enroll ~240 patients each.","Non-inferiority design vs aflibercept; primary endpoint is BCVA change from baseline at weeks 52 and 56.","New preclinical data shows vorolanib inhibits IL-6 mediated inflammation via JAK receptors, adding to VEGF blockade.","Company had positive end-of-Phase 2 meeting with FDA; DURAVYU also in Phase 3 for wet AMD.","Estimated cash and investments as of Sept 30, 2025 included in investor presentation (not specified)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135319,"accession_number":"0000950170-25-103527","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint Q2 net loss $59.4M; completes Phase 3 enrollment for DURAVYU in wet AMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $5.3M, down from $9.5M YoY; net loss $59.4M ($0.85/share) vs. $30.8M ($0.58/share) in Q2 2024.","Total operating expenses $67.6M, up from $44.0M, driven by DURAVYU Phase 3 trial costs.","Cash, equivalents and marketable securities $256M as of June 30, 2025; cash runway into 2027.","Completed enrollment in both Phase 3 wet AMD trials (LUGANO and LUCIA) with over 800 patients; topline LUGANO data mid-2026.","Initiated DURAVYU registration batches at Northbridge, MA commercial manufacturing facility."],"consensus_eps_estimate":-0.813,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":29786000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135318,"accession_number":"0000950170-25-099383","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint finishes Phase 3 enrollment for DURAVYU in wet AMD; top-line data mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LUCIA trial enrolled and randomized over 400 patients in seven months; total >800 across both trials.","Interim safety data consistent with prior DURAVYU trials; DSMC recommended continuation without protocol changes.","Topline 56-week data for LUGANO expected mid-2026; LUCIA data to follow shortly after.","DURAVYU is a sustained-release TKI for wet AMD; Phase 3 program aligned with FDA and EMA.","DURAVYU has been evaluated in over 190 patients across four trials with favorable safety profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135317,"accession_number":"0000950170-25-099413","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K/A","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint completes enrollment in both Phase 3 wet AMD trials for DURAVYU; topline data mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LUCIA enrolled over 400 patients in 7 months; combined LUGANO and LUCIA total over 800 patients.","DSMC interim review confirmed safety consistent with prior trials; no protocol changes, continuation recommended.","Topline 56-week data for LUGANO expected mid-2026; LUCIA topline data to follow shortly after.","DURAVYU is sustained-release TKI with 6-month redosing; evaluated vs on-label aflibercept in non-inferiority design.","Phase 3 program aligned with FDA/EMA; NDA filing targeted after one-year efficacy and safety endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152283,"accession_number":"0000950170-25-088169","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"EyePoint shareholders approve 2.9M share increase to 2023 equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected; say-on-pay approved with ~93% of votes cast.","Plan amendment to add 2,900,000 shares to 2023 Long-Term Incentive Plan passed (41.3M for, 13.0M against).","Stockholders chose annual advisory vote on executive compensation (54.2M votes for 1 year).","Deloitte & Touche ratified as auditor for FY2025 with 60.5M votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152282,"accession_number":"0000950170-25-077373","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint completes Phase 3 LUGANO enrollment for DURAVYU wet AMD; topline data mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 400 patients enrolled/randomized in seven months, one of fastest Phase 3 wet AMD trials.","LUCIA trial 60% randomized; enrollment completion expected Q3 2025.","Topline 56-week LUGANO data mid-2026; LUCIA data in H2 2026.","Phase 3 trials are randomized, double-masked, non-inferiority vs. aflibercept; DURAVYU dosed every 6 months.","DURAVYU is sustained-delivery vorolanib (TKI); potential first sustained-release TKI for wet AMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152281,"accession_number":"0000950170-25-064983","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"EyePoint Q1 net loss $45.2M; DURAVYU Phase 3 wet AMD enrollment over 90% in LUGANO, >50% in LUCIA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $24.5M (up from $11.7M YoY); net loss $45.2M ($0.65 per share) vs $29.3M ($0.55) prior year.","Cash, equivalents, and marketable securities $318.2M; runway into 2027 past Phase 3 topline data expected 2H 2026.","LUGANO trial >90% enrolled, LUCIA >50%; enrollment on track to complete 2H 2025.","Phase 2 VERONA in DME met endpoints; subgroup showed BCVA +10.3 letters vs +3.0 for aflibercept at week 24."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":24453000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171127,"accession_number":"0000950170-25-033065","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint reports Q4 net loss $41.4M; DURAVYU Phase 3 enrollment ahead of expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $41.4M ($0.64/share) vs $14.1M loss prior year; revenue $11.6M down from $14.0M.","Full-year net loss $130.9M ($2.32/share) vs $70.8M loss prior year; revenue $43.3M vs $46.0M.","DURAVYU Phase 3 wet AMD trials LUGANO (>50% enrolled) and LUCIA on track; enrollment completion H2 2025, topline data 2026.","Phase 2 VERONA DME trial met endpoints: BCVA +10.3 letters vs +3.0 control; 43% had absence of DME.","Cash $371M as of Dec 31, 2024; runway into 2027; no equity capital plans for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171126,"accession_number":"0000950170-25-031346","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint posts updated investor presentation for TD Cowen conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated March 4, 2025, was filed as Exhibit 99.1 and posted on company website.","CEO Jay Duker, M.D. is listed as presenter; no new financial or clinical data disclosed in the filing.","No specific updates on product pipeline, revenue, or guidance were included in the provided exhibit.","The filing does not contain any material changes to previously disclosed information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171125,"accession_number":"0000950170-25-014154","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint DURAVYU Phase 2 VERONA meets primary endpoint in DME; 2.7mg shows +7.1 letter BCVA gain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DURAVYU 2.7mg met primary endpoint with extended time to first supplemental injection vs aflibercept.","At week 24, +7.1 letter BCVA gain and 76-micron CST reduction; 73% supplement-free vs 50%.","Favorable safety: no DURAVYU-related ocular or systemic SAEs, no endophthalmitis or retinal vasculitis.","Phase 3 non-inferiority pivotal program planned by end of 2025; FDA meeting in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171124,"accession_number":"0000950170-25-004557","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"EyePoint updates on DURAVYU Phase 3 wet AMD trials enrollment ahead of schedule, Phase 2 DME data expected 1Q 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 LUGANO trial for DURAVYU in wet AMD one-third enrolled; LUCIA trial tracking ahead of schedule; full enrollment target 2H 2025.","Full data from Phase 2 VERONA trial of DURAVYU in DME expected 1Q 2025; interim data showed BCVA gain +8.9 letters and CST improvement.","Cash and investments ~$370M at Dec 31, 2024; cash runway into 2027 beyond Phase 3 wet AMD topline data expected in 2026.","Appointed retina specialist Reginald J. Sanders, M.D., FASRS to Board of Directors.","Opened new 40,000+ sq ft cGMP manufacturing facility in Northbridge, MA to support commercial readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171123,"accession_number":"0000950170-25-003280","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"EyePoint appoints Dr. Reginald Sanders, retina specialist and former ASRS president, to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to nine members; Dr. Sanders appointed effective Jan 8, 2025.","Receives $45,000 annual cash retainer and option for 80,000 shares vesting over 3 years.","Sanders brings expertise as ex-president of American Society of Retina Specialists and PI for Lucentis.","He served as president and managing partner of Retina Group of Washington, largest U.S. retina practice.","Appointment coincides with Phase 3 trials for wet AMD and positive interim Phase 2 DME data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188101,"accession_number":"0000950170-24-133076","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint dosed first patient in second Phase 3 wet AMD trial (LUCIA); topline data expected 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in LUCIA, the second global Phase 3 trial of DURAVYU (vorolanib Durasert E) for wet AMD.","LUCIA follows LUGANO trial; both are randomized, double-masked, non-inferiority vs aflibercept with ~400 patients each.","Primary endpoint: average change in BCVA at weeks 52 and 56; re-dosing every six months.","Topline data from Phase 3 pivotal program anticipated in 2026; over 240 global sites committed.","CEO cites robust interest and strong balance sheet; LUGANO enrollment exceeded expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188100,"accession_number":"0000950170-24-122772","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint Q3 net loss $29.4M; positive DURAVYU interim data, $161M equity financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $29.4M ($0.54 per share) vs. $12.6M loss a year ago; revenue $10.5M down from $15.2M.","Interim Phase 2 VERONA data: DURAVYU 2.7mg showed +8.9 BCVA letters and -68 μm CST improvement at 16 weeks vs. aflibercept.","First patient dosed in Phase 3 LUGANO trial for wet AMD; second Phase 3 LUCIA first patient dosing expected by end of 2024.","Completed $161M oversubscribed public equity offering at $11.00/share; cash runway extended into 2027.","Opened 40,000 sq ft cGMP commercial manufacturing facility in Northbridge, MA for DURAVYU."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":31685000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188099,"accession_number":"0001193125-24-248694","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"EyePoint closes upsized $161M public offering; net proceeds ~$151.1M for DURAVYU development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed offering of 14,636,363 shares at $11.00/share, including full underwriter option exercise for 1,909,090 additional shares.","Net proceeds of ~$151.1M after underwriting discounts and expenses; original offering was upsized from $125M to $161M gross.","Proceeds to fund DURAVYU clinical development for wet AMD & DME, early-stage pipeline, and general corporate purposes.","Joint book-runners: J.P. Morgan, Citigroup, Guggenheim Securities; co-managers: Baird, Mizuho, Jones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188098,"accession_number":"0000950170-24-117568","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"EyePoint reports positive Phase 2 VERONA interim data for DURAVYU in DME; +8.9 letters BCVA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DURAVYU 2.7mg showed +8.9 letter improvement in BCVA vs +3.2 for aflibercept control at 16 weeks.","CST reduction of 68.1 microns vs 30.5 microns for control.","82% of DURAVYU 2.7mg eyes were supplement-free vs 50% for control at 16 weeks.","No DURAVYU-related ocular or systemic SAEs reported; no endophthalmitis, vasculitis, or IOI.","Full topline data from VERONA expected in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188097,"accession_number":"0000950170-24-116847","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint doses first patient in Phase 3 LUGANO trial of DURAVYU for wet AMD; LUCIA trial by end 2024, topline 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in global Phase 3 LUGANO trial of DURAVYU (vorolanib) for wet AMD; non-inferiority design vs aflibercept.","Second Phase 3 LUCIA trial first dosing expected by end of 2024; topline data anticipated in 2026.","Trials enroll ~400 patients each; DURAVYU dosed every 6 months vs on-label aflibercept every 2 months, after 3 loading doses.","Over 190 patients previously treated in DAVIO/DAVIO 2; favorable safety; treatment-naïve and treatment-experienced included.","Re-dosing evaluated in both trials; primary endpoint: average change in BCVA at weeks 52 and 56 vs baseline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204607,"accession_number":"0000950170-24-103097","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"EyePoint Pharma appoints Fred Hassan to board; directors Guyer, Adamis resign for Merck roles","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Guyer and Anthony Adamis resigned from board effective Sept 3, 2024 due to full-time roles at Merck & Co.","Fred Hassan appointed to board; board size reduced from 9 to 8 members.","Hassan received option grant for 60,000 shares vesting over 3 years, annual cash retainer $45k.","Karen Zaderej and Stuart Duty join Compensation Committee (Zaderej as Chair); Hassan joins Governance Committee.","Company nearing first patient dosing in Phase 3 LUGANO trial of DURAVYU for wet AMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204606,"accession_number":"0000950170-24-092262","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint reports Q2 net loss of $30.8M; cash runway through DURAVYU Phase 3 topline in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.8M ($0.58/sh) vs $22.9M loss ($0.61/sh) in Q2 2023; total net revenue $9.5M.","Cash and investments $280.2M at June 30, 2024; expected to fund operations through Phase 3 wet AMD topline data in 2026.","Phase 3 LUGANO wet AMD trial on track for first patient dosing in 2024; LUCIA trial to follow shortly.","Positive 12-month DAVIO 2 data: DURAVYU non-inferior to aflibercept in visual acuity; majority supplement-free.","Phase 2 VERONA (DME) fully enrolled; topline data anticipated Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":21161000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221421,"accession_number":"0000950170-24-077636","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"EyePoint announces Phase 3 plans for DURAVYU in wet AMD; positive Phase 2 data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 LUGANO and LUCIA trials to enroll ~400 patients each; 2.7mg DURAVYU vs aflibercept; one-year endpoint.","Phase 2 DAVIO 2 data: favorable safety, BCVA nearly identical to aflibercept at 12 months post single injection.","After single DURAVYU dose, ~50% of eyes were supplement-free at 12 months vs 22% for aflibercept control.","Phase 2 VERONA trial in DME fully enrolled with 27 patients; no drug-related SAEs reported.","First patient dosing in Phase 3 LUGANO expected 2H 2024; FDA alignment on non-inferiority design with redosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221420,"accession_number":"0000950170-24-075872","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"EyePoint shareholders approve 4M share increase for 2023 LTIP, 250K for ESPP at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved amendment to 2023 Long-Term Incentive Plan: authorized shares increased by 4,000,000.","Non-employee director compensation limit raised to $850,000 (ongoing) and $1,100,000 (new directors) per year.","Approved amendment to 2019 Employee Stock Purchase Plan: shares increased by 250,000.","All eight director nominees elected; say-on-pay and ratification of Deloitte as auditor passed.","LTIP amendment received 28.4M for, 15.9M against; ESPP amendment received 44.1M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221419,"accession_number":"0000950170-24-064879","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint posts updated investor presentation; no specific financial updates in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed investor presentation dated May 2024 as Exhibit 99.1 on May 28, 2024.","Presentation posted on company website at www.eyepointpharma.com.","No new financial guidance, clinical data, or material events disclosed in filing summary.","Ticker EYPT; common stock listed on Nasdaq.","No changes to previously disclosed business outlook or pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221418,"accession_number":"0000950170-24-055055","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint Q1 net loss $29.3M; DURAVYU Phase 2 NPDR trial misses primary endpoint; cash runway to 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $29.3M ($0.55/shr) vs $21.2M ($0.56/shr) in Q1 2023; revenue $11.7M (+52% YoY) from YUTIQ deferred revenue.","Product revenue fell to $0.7M from $7.4M due to out-license of YUTIQ franchise in May 2023.","Phase 2 PAVIA trial of DURAVYU in NPDR missed primary endpoint; biologic effect observed; 12-month data expected Q3 2024.","Phase 3 LUGANO trial for DURAVYU in wet AMD on track for 2H 2024; Phase 2 VERONA DME data in Q1 2025.","Cash and investments $299.3M; funds operations through DURAVYU Phase 3 topline data in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":11684000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221417,"accession_number":"0000950170-24-053248","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint's DURAVYU misses Phase 2 NPDR primary endpoint; shows reduced progression at 9 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint not met: 5% (3mg), 0% (2mg) vs 5% control achieved ≥2-step DRSS improvement at 9 months.","86% (3mg) and 80% (2mg) patients stable/improved vs 70% control; 0% (3mg) worsened ≥2-step vs 10% control.","No drug-related serious adverse events reported; favorable safety profile maintained.","Company on track for Phase 3 wet AMD trial (LUGANO) in H2 2024 and DME trial (VERONA) data in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240966,"accession_number":"0000950170-24-027582","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"EyePoint reports Q4/FY2023 results; positive Phase 2 data for EYP-1901 in wet AMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $14.1M ($0.33/sh) vs $43.5M ($1.16/sh) YoY; total net revenue $14.0M (+33%).","Cash and investments $331M as of Dec 31, 2023, funding operations through Phase 3 topline data for wet AMD in 2026.","Positive Phase 2 DAVIO 2 data: EYP-1901 met all primary/secondary endpoints; first Phase 3 trial expected 2H 2024.","First patient dosed in Phase 2 VERONA trial for DME; topline data 1Q 2025; PAVIA NPDR data expected 2Q 2024.","Appointed Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240965,"accession_number":"0000950170-24-024346","cik":1314102,"company_name":"EyePoint, Inc.","ticker":"EYPT","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EyePoint names Ramiro Ribeiro as Chief Medical Officer, replaces Dario Paggiarino","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ramiro Ribeiro appointed CMO effective March 1, 2024; succeeds Dario Paggiarino who leaves March 31.","Ribeiro joins from Apellis, where he led global Phase 3 GA program and FDA approval of SYFOVRE.","Company on track to report Phase 2 PAVIA topline data for EYP-1901 in NPDR in Q2 2024.","Initiation of Phase 3 LUGANO trial for EYP-1901 in wet AMD expected in second half 2024.","Board granted 125,000 stock options as inducement award to Ribeiro under Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1158686659.9346504,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}